Highest-materiality recent filing
Kymera completes enrollment in Phase 2b KT-621 AD trial; topline data accelerated to year-end 2026
Enrollment in BROADEN2 completed nearly six months ahead of schedule; topline data now expected by year-end 2026.
Kymera annual meeting results: all Class III directors elected, say-on-pay approved, EY ratified
Elected Bruce Booth, Nello Mainolfi, John Maraganore, Elena Ridloff as Class III directors for 3-year terms.
Kymera Therapeutics COO Jeremy Chadwick resigns effective June 5, 2026; will advise through Nov 2026
COO Jeremy Chadwick resigned for personal reasons, not due to any disagreement with company policies.
Kymera reports Q1 net loss $69.2M; Gilead licenses KT-200 for $45M milestone
Net loss $69.2M in Q1 2026, vs $65.6M in Q1 2025; cash $1.55B provides runway into 2029.
Kymera Therapeutics amends bylaws to designate federal courts for securities claims
Board approved amendment to Second Amended and Restated Bylaws on March 25, 2026.
Kymera reports FY2025 net loss $311M; cash $1.6B; STAT6 and IRF5 trials advancing
Cash and investments of $1.6B as of Dec 31, 2025, providing runway into 2029.
Kymera Therapeutics enters $500M at-the-market offering agreement with TD Cowen
Agreement allows Kymera to sell up to $500M of common stock through TD Cowen at its discretion.
Kymera reports $1.6B cash; KT-621 Phase 2b AD data by mid-2027, asthma data late-2027
Preliminary cash, cash equivalents and marketable securities of $1.6B as of Dec 31, 2025; runway into 2029.
Kymera prices upsized $602M public offering; net ~$656M for pipeline
Priced 7,000,000 shares at $86.00 per share; gross proceeds $602M.
Kymera reports positive Phase 1b results for oral STAT6 degrader KT-621 in atopic dermatitis
KT-621 achieved 98% median STAT6 degradation in blood and 94% in skin lesions at Day 29 across both dose groups.
Kymera discusses Phase 1b data for KT-621 in atopic dermatitis on Dec 8 call
Oral STAT6 degrader KT-621 BroADen Phase 1b results presented; slide deck furnished.
Kymera Q3 net loss $82.2M; KT-621 Phase 1b AD data due Dec 2025
Net loss $82.2M in Q3 2025 vs $62.5M in Q3 2024; R&D expenses rose to $74.1M.
Kymera Therapeutics appoints Brian Adams as Chief Legal Officer; Ellen Chiniara retires
Ellen Chiniara, Chief Legal Officer, retires effective Sept 3, 2025; departure not due to any disagreement with the company.
Kymera Q2 net loss $76.6M; cash ~$1B; KT-621 Phase 1 data positive; Gilead CDK2 deal up to $750M
Net loss widened to $76.6M in Q2 2025 ($42.1M Q2 2024); R&D spend rose to $78.4M from $59.2M.
Kymera shareholders elect Albers and Baker as Class II directors at 2025 annual meeting
Jeffrey Albers elected with 55,765,189 votes for, 3,142,251 withheld.
Kymera prices $250.8M public offering of common stock and pre-funded warrants
Offering includes 5,044,500 shares at $44.00 and pre-funded warrants for 655,500 shares at $43.9999.
Kymera and Gilead sign option/license deal for CDK2 degraders; up to $750M
Up to $750M total payments including $85M upfront/option exercise payments.
Sanofi to advance Kymera's KT-485 IRAK4 degrader; $20M milestone achieved
Sanofi selects KT-485 for Phase 1 testing in immuno-inflammatory diseases, expected to start next year; KT-474 will not advance.
SAD: >90% mean STAT6 degradation in blood at doses starting at 6.25 mg; ≥75 mg achieved complete degradation.
Kymera presents Phase 1 healthy volunteer data for oral STAT6 degrader KT-621
Hosted conference call on June 2, 2025 to discuss Phase 1 results for KT-621, a first-in-class oral STAT6 degrader.
Kymera Q1 net loss $65.6M, cash $775M; unveils oral IRF5 degrader KT-579; STAT6 data June
Net loss $65.6M (Q1 2025) vs $48.6M (Q1 2024); collab revenue $22.1M incl $20M Sanofi milestone.
Kymera grants PSUs to key employees with three clinical milestone vesting targets
PSUs vest in three installments: 40% for first milestone, 40% for second, 20% for third.
Kymera Q4 net loss $70.8M, cash $851M; KT-621 Phase 1 data June 2025
Net loss Q4 2024 $70.8M, full year $223.9M; collaboration revenue Q4 $7.4M vs $47.9M YoY.
Kymera reports $850M cash, outlines 2025 pipeline milestones for KT-621, KT-295, KT-474
Preliminary cash ~$850M as of Dec 31, 2024; runway into mid-2027.
Kymera posts Q3 net loss $62.5M; initiates STAT6 degrader Phase 1; shifts focus to immunology
Net loss $62.5M in Q3 2024 vs $52.9M in Q3 2023; collaboration revenue $3.7M from Sanofi.
Kymera prices $225M offering of common stock and pre-funded warrants
Selling 2,002,313 shares at $40.75 and 3,519,159 pre-funded warrants at $40.7499.
Kymera Q2 net loss $42.1M, cash $702M; Sanofi expands KT-474 Phase 2
Net loss $42.1M in Q2 2024 vs $38.8M in Q2 2023; revenue from Sanofi collaboration $25.7M.
Sanofi expands KT-474 Phase 2 trials in HS and AD after positive interim data review
Sanofi to expand ongoing Phase 2 trials for KT-474 in hidradenitis suppurativa and atopic dermatitis.
Director Joanna Horobin resigned from board and all committees on June 18, 2024; resignation not due to any disagreement.
Kymera Therapeutics Q1 2024 net loss $48.6M; cash $745M; pipeline progresses
Net loss $48.6M in Q1 2024 vs $40.9M in Q1 2023; collaboration revenue $10.3M.
Kymera appoints Felix J. Baker as director and Lead Independent Director
Felix J. Baker appointed to Board as Class II director effective March 28, 2024; also named Lead Independent Director.
Kymera Q4 net loss $14.4M, cash $745M; KT-474 Phase 2 data due H1 2025
Net loss $14.4M in Q4, $147.0M for FY2023; collaboration revenue $47.9M Q4, $78.6M FY.
Kymera prices $275M public offering of common stock and pre-funded warrants
Priced public offering of 2.25M shares at $25.25 and 8.64M pre-funded warrants at $25.2499; gross proceeds ~$275M.
KT-621 (STAT6 degrader) expected to enter Phase 1 in H2 2024; preclinical data shows superior efficacy to dupilumab.
Kymera holds immunology R&D day; discloses new targets and clinical timelines
Company held virtual immunology R&D day on Jan 4, 2024, highlighting emerging pipeline.
Kymera reports Q3 net loss $52.9M; initiates Phase 2 HS trial, receives $40M milestone
Net loss of $52.9M in Q3 2023 vs $43.0M loss in Q3 2022; revenue $4.7M down from $9.6M.
Kymera reports Phase 1 data for STAT3 degrader KT-333: one PR in CTCL, no DLTs
21 patients enrolled through dose level 5; 12 evaluable for disease assessment.
Kymera Q2 net loss $38.8M; cash $472M; Sanofi to start KT-474 Phase 2 in Q4 2023
Collaboration revenue $16.5M (up from $11.5M YoY); R&D expense $45.8M; net loss narrowed to $38.8M.
Elected Bruce Booth, Nello Mainolfi, John Maraganore, Elena Ridloff as Class III directors for three-year terms.
Kymera appoints Jeremy Chadwick as COO; base salary $480K, equity grants
Jeremy Chadwick, Ph.D., appointed COO effective May 22, 2023; previously SVP at Takeda.
Kymera reports Q1 net loss of $40.9M, cash $516M; initiates MDM2 degrader trial
Net loss $40.9M vs $36.7M Q1 2022; R&D expenses $42.2M (up from $35.9M).
Kymera reports limited SVB exposure of $2.2M cash and $4.5M letter of credit
As of March 10, 2023, Kymera holds $2.2M cash at Silicon Valley Bank (SVB) and $4.5M restricted cash letter of credit.
Kymera Therapeutics CBO Elaine Caughey to depart April 10, 2023
Chief Business Officer Elaine Caughey departing for personal family reasons.
Kymera reports Q4 2022 net loss $34.9M; cash $559.5M; Sanofi to start KT-474 Phase 2 in 2023
Net loss Q4 2022: $34.9M, full year $154.8M; cash and investments $559.5M as of Dec 31, 2022, runway into H2 2025.
Kymera reports ~$560M cash, 2023 pipeline goals including KT-474 Phase 2 start with Sanofi
Preliminary cash, cash equivalents and investments of ~$560M as of Dec 31, 2022, runway into H2 2025.
KT-474 achieved >90% IRAK4 degradation in blood and skin; cytokine inhibition up to 98% in AD and 84% in HS; no serious AEs.
Kymera provides clinical update on KT-474 Phase 1 Part C in HS & AD; oncology pipeline update
Held virtual investor event to present Part C Phase 1 data for KT-474 (IRAK4 degrader) in hidradenitis suppurativa and atopic dermatitis.
Kymera Q3 2022 net loss $43M, cash $596M; board adds Sandor as Nicholson resigns
Q3 2022 net loss $43.0M ($0.81/sh) vs $28.6M in Q3 2021; collaboration revenue $9.6M vs $20.3M.
Kymera completes KT-474 Phase 1 Part C dosing; webcast Dec 14 for data
Completed dosing in Part C of KT-474 Phase 1 trial for hidradenitis suppurativa and atopic dermatitis.
Kymera raises $150M PIPE with 2.77M shares at $26 and 3M pre-funded warrants
Private placement of 2,769,228 common shares at $26.00 and 3,000,000 pre-funded warrants at $25.9999.
Jeremy Chadwick communicated his intention to retire and submitted his resignation as Chief Operating Officer (“COO”) on June 5, 2026.
On February 24, Leigh Morgan, a member of the Board of Directors (the “Board”) of the Company, the Compensation and Talent Committee of the Board, and a member and chair of the Nominating and Corporate Governance Committee of the Board, informed the Company that she does not intend to stand for reelection at the Company’s 2025 annual meeting of shareholders.
On June 18, 2024, Joanna Horobin, M.B., Ch.B. a member of the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) and the Audit Committee of the Board (the “Audit Committee”) and Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), notified the Company of her resignation from the Board and all committees thereof, effective immediately.
On March 28, 2024, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”), the Board appointed Felix J. Baker, Ph.D. to join the Board, effective March 28, 2024.
On May 22, 2023, Kymera Therapeutics, Inc. (the “Company”) announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer effective as of May 22, 2023.
Elaine Caughey, its Chief Business Officer, will be departing the Company for personal family reasons effective as of April 10, 2023.
On November 1, 2022, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Victor Sandor, M.D. to join the Board, effective as of November 3, 2022.
On October 31, 2022, Donald Nicholson, Ph.D., a member of the Board of Directors (the “Board”) of the Company and the Compensation Committee of the Board, notified the Company of his resignation from the Board and all committees thereof, effective November 3, 2022.
the Board appointed Leigh Morgan to join the Board, effective as of July 6, 2022.
On April 6, 2022, Dr. Steven Hall, a member of the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) and the Compensation Committee of the Board, informed the Company that he does not intend to stand for reelection at the Company’s 2022 annual meeting of stockholders
the Board appointed John Maraganore, Ph.D. to join the Board, effective as of January 17, 2022.
On September 16 th , 2021, Kymera Therapeutics, Inc. (the “Company”) announced that Richard Chesworth, its Chief Scientific Officer, will be departing the Company effective as of October 22 nd 2021.
Max materiality 0.90 · Median 0.65 · Most common event other_material